Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies
ConclusionOur findings indicate that fluoropyrimidine can be an immunologically optimal partner of ICIs through the induction of ICD for thoracic malignancies. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 26, 2023 Category: Cancer & Oncology Authors: Hiroyuki Kozai,
Hirokazu Ogino,
Atsushi Mitsuhashi,
Na Thi Nguyen,
Yuki Tsukazaki,
Yohei Yabuki,
Ryohiko Ozaki,
Hiroto Yoneda,
Seidai Sato,
Masaki Hanibuchi,
Tsutomu Shinohara,
Hiroshi Nokihara,
Yasuhiko Nishioka Tags: ORIGINAL ARTICLE Source Type: research
A dynamic Boolean network reveals that the BMI1 and MALAT1 axis is associated with drug resistance by limiting miR-145-5p in non-small cell lung cancer
In conclusion, targeting MALAT1 and BMI1 holds promise for overcoming drug resistance, while activating miR-145 represents a potential strategy to significantly reduce drug resistance in NSCLC.PMID:38125755 | PMC:PMC10730431 | DOI:10.1016/j.ncrna.2023.10.008 (Source: Cell Research)
Source: Cell Research - December 21, 2023 Category: Cytology Authors: Shantanu Gupta Daner A Silveira Gabriel P S Piedade Miguel P Ostrowski Jos é Carlos M Mombach Ronaldo F Hashimoto Source Type: research
Long ‑term survival of a patient with advanced lung cancer treated with targeted therapy and anti‑PD‑1 immunotherapy as multi‑line therapy: A case report
In conclusion, the present case demonstrated the efficacy of targeted therapy and anti-PD-1 immunotherapy for the treatment of advanced lung cancer following the occurrence of drug resistance and progressive disease.PMID:38108071 | PMC:PMC10722554 | DOI:10.3892/ol.2023.14166 (Source: Oncology Letters)
Source: Oncology Letters - December 18, 2023 Category: Cancer & Oncology Authors: Tianhao Guo Wenjian Zhu Shuoqi Zhao Wenli Qiu Yan Wu Xuan Li Fei Ke Haibo Cheng Source Type: research
Cytokine Release Syndrome More than Two Years after Pembrolizumab Introduction: A Case Report
In conclusion, CRS can occur even long after the initial administration of immune checkpoint inhibitor therapy.PMID:38104995 | DOI:10.2169/internalmedicine.2347-23 (Source: Internal Medicine)
Source: Internal Medicine - December 17, 2023 Category: Internal Medicine Authors: Kazuhisa Nakashima Kashu Kitani Kento Kono Ken Yoshihara Keita Kawakado Misato Kobayashi Takae Okuno Yoshihiro Amano Yukari Tsubata Takeshi Isobe Source Type: research
